Explore our comprehensive portfolio that addresses the complete care continuum for many of the world’s most threatening diseases. 

Discover the stories of pioneers pushing the boundaries of what’s possible in healthcare to help improve people’s lives around the world.

Patient-centered innovation has been and always will be at the core of our company. Dive deeper into our fascinating technologies.

We pioneer breakthroughs in healthcare. For everyone. Everywhere. Learn more about our purpose, our innovation leadership, our culture, and our strategy.

  1. Home

  2. Press center
  3. Press releases
  4. Siemens Healthineers Starts Delivery of Test Kit for Coronavirus SARS-CoV-2, Now CE-IVD Registered
Press release

Siemens Healthineers Starts Delivery of Test Kit for Coronavirus SARS-CoV-2, Now CE-IVD Registered

Published on April 30, 2020

COVID-19
The SARS-CoV-2 virus, which is the cause of the COVID-19 outbreak.

Download this press release(pdf, 68.01 KB)

1

In method comparison studies, FTDSARS-CoV-2 has shown 100% (91.8-100, 95% CI) diagnostic sensitivity and 100% (93.8-100, 95% CI) diagnostic specificity when tested in Copan eSwab nasopharyngeal and oropharyngeal swabs.

2

CE-IVD labelled for diagnostic use in the EU. For research use only (RUO) in the U.S. Pursuing FDA emergency use authorization (EUA) and WHO emergency use listing (EUL).

3

CE-IVD labelled for diagnostic use in the EU. For research use only (RUO) in the U.S.

4

Under development. Not available for sale. Future availability cannot be guaranteed.

Product availability varies by country and is subject to local regulatory requirements.

Siemens Healthineers 2020

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of Healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalising healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care to patients. In fiscal 2020, which ended on September 30, 2020, Siemens Healthineers, which has approximately 54,000 employees worldwide, generated revenue of €14.5 billion and adjusted EBIT of €2.2 billion.